Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Autifony Awarded £2.2 Million to Progress AUT00063 for Tinnitus into Phase IIa Study

Published: Wednesday, June 04, 2014
Last Updated: Wednesday, June 04, 2014
Bookmark and Share
Award follows successful completion of Phase I.

Autifony Therapeutics Limited has announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board.

Autifony will be sponsor of the clinical study, with Professor Deborah Hall at The University of Nottingham and National Institute for Health Research (NIHR) Nottingham Hearing Biomedical Research Unit (BRU) as lead academic collaborator.

AUT00063 is a first-in-class Kv3 potassium channel modulator in development for the treatment of age-related hearing loss, for which a Phase IIa clinical trial is expected to start later this year. The Technology Strategy Board funding award will now enable Autifony to initiate a randomized, placebo controlled Phase IIa study in patients with tinnitus in the UK, allowing Autifony to test the drug’s efficacy in this poorly served patient group.

The award follows an application to the Biomedical Catalyst, jointly funded by the Technology Strategy Board and the Medical Research Council, and comes after the recent successful completion of a randomized, placebo controlled Phase I study, conducted in the UK, which investigated the safety, tolerability and pharmacokinetics of orally administered single and multiple dose regimens of AUT00063 in more than 60 young and elderly healthy volunteers.

In the study the drug appeared safe and well tolerated, and no serious adverse events were recorded. AUT00063 showed excellent pharmacokinetics, compatible with once/daily oral dosing.

The Phase I trial also explored a variety of novel pharmacodynamic endpoints and interactions, which confirmed the engagement of the drug with the Kv3 ion channel target, and provided further supporting evidence for dose selection in the Phase II studies.

Dr Charles Large, Chief Executive Officer of Autifony, commented: “There is a huge need for a drug to treat tinnitus, which is surprisingly common, affecting over 10% of the population. Tinnitus seriously impacts quality of life for up to 1% of people, disrupting sleep and concentration, as well as affecting their hearing and emotional state. We are very hopeful that our pioneering Kv3 channel modulator approach may be able to bring some relief to patients with tinnitus, although there is clearly still a long development path ahead of us. The Technology Strategy Board funding will be very helpful in enabling us to test AUT00063 in this additional indication with such high unmet medical need."

Dr Ralph Holme, Head of Biomedical Research at Action on Hearing Loss, the UK charity dedicated to hearing loss research, commented: “On a daily basis we are contacted by people who struggle to cope with their tinnitus and want to know if there are effective treatments for this condition. We are delighted that Autifony, who we have worked with closely from their inception, has secured funding to continue clinical testing on a potential new drug treatment that we hope will bring relief to tinnitus sufferers.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Dr John Hutchison Joins Autifony Therapeutics as Chief Medical Officer
Dr Hutchison brings a wealth of experience of clinical drug development in both big pharma and the biotech sector.
Friday, September 04, 2015
Autifony Initiates Phase I Study for AUT00063 for Hearing Loss and Tinnitus Treatment
Company tops up Series A financing with further £5.5 million investment.
Monday, June 10, 2013
Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!